Revenue - Development and Commercialization Agreement (Details)	1 Months Ended				3 Months Ended								12 Months Ended
	Jun. 30, 2019 USD ($)	Apr. 30, 2018 plan	Feb. 28, 2018	Jan. 31, 2015	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Collaborative Arrangements and Co-Promote Agreement
Milestone payment					$ 18,730,000	$ 18,257,000	$ 15,008,000	$ 19,862,000	$ 29,499,000	$ 12,427,000	$ 26,150,000	$ 5,338,000	$ 71,857,000	$ 73,414,000	$ 60,370,000
Percentage of profit share			33.00%										35.00%
YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Milestone payment					13,550,000	$ 12,960,000	$ 10,589,000	12,880,000	$ 10,352,000	$ 5,763,000	3,184,000	$ 1,000
Viatris
Collaborative Arrangements and Co-Promote Agreement
Upfront payment receivable	$ 18,500,000
Potential milestone or contingent payments								$ 1,500,000
Transaction price					34,200,000								$ 34,200,000
Number of performance obligations													2
Performance period (in years)				17 years									11 years
Deferred revenue					300,000								$ 300,000
Percentage of profit share													65.00%
Viatris | Purchase Agreement
Collaborative Arrangements and Co-Promote Agreement
Premium proceeds from sale of ordinary shares																	$ 4,200,000
Viatris | Development and Commercialization Agreement
Collaborative Arrangements and Co-Promote Agreement
Initial cash payment													$ 30,000,000.0				$ 15,000,000.0
Viatris | Revefenacin Monotherapy (TD-4208)
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments					160,000,000.0								160,000,000.0
Viatris | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	9,000,000.0										9,000,000.0
Viatris | YUPELRI Monotherapy | Development and Commercialization Agreement
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments					160,000,000.0								160,000,000.0
Viatris | Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	7,500,000				45,000,000.0						7,500,000		45,000,000.0
Viatris | Milestone - 50% enrollment in Phase 3 twelve-month safety study | Development and Commercialization Agreement
Collaborative Arrangements and Co-Promote Agreement
Milestone payment																$ 15,000,000.0
Viatris | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	37,500,000				205,000,000.0						37,500,000		205,000,000.0
Viatris | Sales milestones | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments					150,000,000.0								150,000,000.0
Viatris | Regulatory actions | YUPELRI Monotherapy
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments					10,000,000.0								$ 10,000,000.0
Viatris | Development and Sales Milestones | Future potential combination products
Collaborative Arrangements and Co-Promote Agreement
Potential milestone or contingent payments	$ 54,000,000.0										$ 54,000,000.0
Pfizer
Collaborative Arrangements and Co-Promote Agreement
Initial cash payment														10,000,000.0
Number of performance obligations													2
Pfizer | Sales milestones
Collaborative Arrangements and Co-Promote Agreement
Milestone payment														240,000,000.0
Alfasigma
Collaborative Arrangements and Co-Promote Agreement
Number of performance obligations | plan		5
Performance period (in years)													6 years
Deferred revenue					$ 200,000								$ 200,000
Alfasigma | Development and Commercialization Agreement
Collaborative Arrangements and Co-Promote Agreement
Milestone payment														$ 100,000	$ 10,700,000